Bayer's New CFO Faces a Rocky Start as Judge Blasts $7.25 Billion Roundup Deal

Judith Hartmann inherits Bayer's €30B debt and a contested $7.25B Roundup settlement as CEO Anderson's cost cuts boost stock 53%.

Judith Hartmann doesn't get a honeymoon period. When she officially takes the reins as Bayer's chief financial officer on June 1, 2026, she'll inherit a balance sheet under siege — a net loss of €3.6 billion, net financial debt hovering near €30 billion, and a legal time bomb that just got louder.

A US federal judge in San Francisco has thrown a wrench into the German conglomerate's carefully laid plans to contain its Roundup liabilities. Vince Chhabria, who oversees thousands of cancer lawsuits against Bayer, described the proposed $7.25 billion class-action settlement from Missouri as "astonishing" and "legally problematic" during a recent hearing. He questioned whether a deal struck in one state court could legally bind plaintiffs in others — particularly those who used Roundup but haven't yet developed cancer and therefore haven't filed lawsuits.

The judge took particular issue with the opt-out provisions, calling them "bizarre." Affected individuals are expected to decide by this summer whether to join the settlement — before the Supreme Court issues a pivotal ruling that could reshape the entire legal landscape.

Bayer, however, is pressing ahead. The company said it believes there's sufficient support among plaintiffs for approval by the judge in St. Louis, who will hear objections and make a final decision in July 2026. Chhabria declined to block the settlement outright but left the door open to revisit the issue if a plaintiff in his court objects.

A Balance Sheet Under Pressure

The legal overhang is just one piece of the puzzle Hartmann must solve. Wolfgang Nickl, her predecessor who retires after nearly a decade in the role, used his final annual general meeting in April to rule out equity raises as a financing option. Instead, Bayer is tapping existing credit lines and exploring structured finance products.

The numbers tell a sobering story. Since acquiring Monsanto for $63 billion in 2018, Bayer has already spent more than $10 billion on settlements, with roughly 65,000 claims still outstanding. The company expects around €5 billion in cash outflows from litigation alone in 2026.

Hartmann joins a board that's already deep in transformation mode. CEO Bill Anderson's restructuring program — known as the DSO model — has eliminated over 12,000 positions globally and slashed management layers. The goal is sustainable cost savings of €2 billion by year-end.

Market Sentiment Holds Up — For Now

Despite the legal noise, investors have rewarded Bayer's cost-cutting discipline. The stock has climbed more than 53 percent over the past twelve months, trading at €37.12 — comfortably above its long-term average. Yet the shares remain roughly 24 percent below their 52-week high, a gap that underscores how Roundup liability continues to cap valuation.

Technical indicators suggest the rally may be overheated in the near term, with a high RSI reading signaling a stretched position. But the fundamental picture offers some support: Bayer is targeting revenue of up to €47 billion for the current year, with operating earnings before special items expected to exceed €10 billion.

A Pivotal Quarter Ahead

Bayer reports first-quarter results on May 12, 2026, and legal provisions are expected to dominate the discussion. The convergence of a contested settlement, a Supreme Court ruling on the horizon, and a leadership transition in the finance department creates a uniquely volatile moment for the stock.

Hartmann, who joined the board in March after stints at ENGIE and Bertelsmann, knows the playbook for navigating corporate turnarounds. But the scale of Bayer's challenges — a debt load approaching €30 billion, a net loss of €3.6 billion, and a legal saga that refuses to fade — will test her from day one. The board has already extended the contracts of Anderson and other executives, signaling confidence in the current strategy. Whether that confidence is warranted will become clearer as the summer unfolds.